Ababax is an early stage company working towards the translation of scientific findings into therapeutic approaches based on digital, non-invasive sensory stimulation.

Dopavision is a therapeutic company developing a digital therapeutic for myopia. Myopia, or shortsightedness, is a condition where the visual image is focused in front of the retina, instead of on the retina itself, as it should. People with myopia have good near sight vision but poor distance vision. Dopavision is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated with the use of a smartphone. Myopia is a visual condition that affects on average every third person globally, a share that has increased rapidly during the last two decades. The goal of the Berlin-based startup is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Federal Ministry of Education and Research) with the amount of € 1.4 million over three years.

The utmost focus of anything we do is to positively impact the patients’ health journey. Four departments closely collaborate within our team: The discovery team explores how scientific breakthroughs and revolutionary technologies can combine to add value for patients worldwide. Our applied scientists conduct clinical trials and prove the efficacy of new Digital Drugs. Based on this scientific evidence and under strict regulations, our dev team develops innovative Software-as-a-Drug solutions. Finally, operational management ensures an efficient workflow.

Dopavision is pioneering the development of digital therapeutics in ophthalmology. We are developing a game-changing therapeutic for childhood myopia which can be easily administered by using a smartphone app. Our goal is to provide a clinically validated therapeutic to help in the fight against the global myopia crisis.